2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
Dolutegravir’s patent expiry will pile on the pressure as Gilead and Merck get on the long-acting bandwagon.
And Gilead has plans for its biannual injection in pre-exposure prophylaxis, too.
Gilead’s dominance of the HIV prevention market is set to be challenged by monotherapy.
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.